全文获取类型
收费全文 | 3281篇 |
免费 | 237篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 74篇 |
儿科学 | 61篇 |
妇产科学 | 78篇 |
基础医学 | 498篇 |
口腔科学 | 46篇 |
临床医学 | 288篇 |
内科学 | 763篇 |
皮肤病学 | 45篇 |
神经病学 | 270篇 |
特种医学 | 216篇 |
外科学 | 426篇 |
综合类 | 104篇 |
一般理论 | 2篇 |
预防医学 | 151篇 |
眼科学 | 27篇 |
药学 | 305篇 |
中国医学 | 8篇 |
肿瘤学 | 187篇 |
出版年
2023年 | 21篇 |
2022年 | 57篇 |
2021年 | 107篇 |
2020年 | 49篇 |
2019年 | 64篇 |
2018年 | 86篇 |
2017年 | 69篇 |
2016年 | 73篇 |
2015年 | 78篇 |
2014年 | 117篇 |
2013年 | 171篇 |
2012年 | 264篇 |
2011年 | 286篇 |
2010年 | 158篇 |
2009年 | 117篇 |
2008年 | 208篇 |
2007年 | 214篇 |
2006年 | 214篇 |
2005年 | 164篇 |
2004年 | 181篇 |
2003年 | 156篇 |
2002年 | 146篇 |
2001年 | 38篇 |
2000年 | 38篇 |
1999年 | 38篇 |
1998年 | 23篇 |
1997年 | 27篇 |
1996年 | 22篇 |
1995年 | 19篇 |
1994年 | 8篇 |
1993年 | 9篇 |
1992年 | 24篇 |
1991年 | 22篇 |
1990年 | 17篇 |
1989年 | 18篇 |
1988年 | 14篇 |
1987年 | 17篇 |
1986年 | 17篇 |
1985年 | 29篇 |
1984年 | 14篇 |
1983年 | 17篇 |
1982年 | 11篇 |
1981年 | 10篇 |
1980年 | 13篇 |
1978年 | 8篇 |
1976年 | 11篇 |
1975年 | 12篇 |
1974年 | 10篇 |
1973年 | 10篇 |
1972年 | 8篇 |
排序方式: 共有3549条查询结果,搜索用时 15 毫秒
21.
Sheldon C. Siegel M.D. Roger M. Katz M.D. Gary S. Rachelefsky M.D. Milan L. Brandon M.D. Lowell A. Borgen Ph.D. 《The Journal of allergy and clinical immunology》1985,75(6):698-705
Procaterol hydrochloride, a potent beta 2-adrenergic bronchodilator developed in Japan, was evaluated in a double-blind, placebo-controlled study for efficacy and safety in 45 patients (ages 18 to 55 yr) with chronic documented reversible airway disease. After a 1-week placebo washout period, patients were administered either 0.05 mg or 0.10 mg of procaterol or placebo twice daily for 2 wk. Spirometric determinations, vital signs, and ECGs were obtained at 1/2, 1, 2, 4, 6, and 8 hr after the first dose and at the same time intervals after 1 and 2 wk of treatment. Patients recorded on a daily basis peak flow rates, asthma symptoms, need for supplemental aerosol, concurrent medications, and side effects. Spirometry results indicated significant improvement in pulmonary function with both doses of procaterol compared with placebo (P less than 0.05). The larger dose was generally more effective. Bronchodilatation was evident 1/2 hr after dosing and peaked at 2 hr. At 8 hr after 0.10 mg of procaterol, FEV1 was still above predose values. Daily peak flow rates were significantly higher with 0.10 mg than with 0.05 mg (P less than 0.05) and placebo (P less than 0.001). Tremor and nervousness were the most frequent side effects. They occurred in a dose-related frequency, were mild and transient, and occurred early in treatment. No significant drug-related changes were noted in ECGs, heart rate, blood pressure, or clinical laboratory data. Procaterol was found to be an effective, well-tolerated oral bronchodilator with a long duration of action, especially at 0.10 mg twice daily. 相似文献
22.
Ivana Vančurová Miroslav Flieger Jindřich Volc Milan J. Beneš Jana Novotná Jiří Neužil Vladislav Běhal 《Journal of basic microbiology》1987,27(9):529-533
Anhydrotetracycline oxygenase was purified both by affinity chromatography and by hydrophobic interaction chromatography. Molecular weight of anhydrotetracycline oxygenase was determined to be 115,000 by Sephadex G-200 gel filtration. Using preparative isoelectric focusing the isoelectric point of the enzyme was estimated to be 5.3. The enzyme showed a sensitivity to thiol-specific inhibitors. During the hydrophobic interaction purification step, the activity dropped considerably. Reactivation occurred when a heat treated crude extract was added to the reaction mixture. 相似文献
23.
Ariano RE Demianczuk RH Danzinger RG Richard A Milan H Jamieson B 《The Canadian journal of hospital pharmacy》1995,48(5):284-289
A one-year pilot project was performed to assess the economic and clinical benefit of pharmacist involvement on the surgical wards of a 600-bed tertiary care, teaching hospital. A total of 405 recommendations were collected with a physician acceptance rate of 90%. From these recommendations, 1416 patient follow-ups were performed to document outcome. The total documented cost avoidance of the pharmacists' activities was $33,265.58. The total annual drug expenditure for the department of surgery declined by $59,662 representing a 9% decrease over the previous year with the greatest decline involving antimicrobials which decreased by $52,587 compared with the previous year. Most of the cost-avoidance in this area was attributable to antimicrobial selection and dosing adjustment in renal impairment. Pharmacist-directed pharmacokinetic monitoring of aminoglycosides resulted in a clinical success rate of 93.8% for treatment regimens and a 6.2% incidence of nephrotoxicity. Housestaff education aimed at improving prescribing practices were identified and provided for select agents including midazolam, ketorolac, vancomycin and aminoglycosides. As well, select recommendations were documented which illustrated the benefit to patient care of pharmacist involvement. Pharmacist involvement on the surgery services produced both financial and clinical benefits. 相似文献
24.
Milan Slavik P. Y. Liu Eric H. Kraut Ronald B. Natale Lawrence E. Flaherty Vernon K. Sondak 《Investigational new drugs》1995,13(2):143-147
Merbarone, NSC 336628, is an investigational anticancer drug with activity against experimental animal tumors including melanoma. This paper presents results of a Phase II clinical study of merbarone in patients with biopsy proven stage IV malignant melanoma without prior chemotherapy and with no evidence of CNS involvement. Thirty-five patients with median age 58 (range 27–81), with performance status 0–2 were treated with merbarone 1000 mg/m2/day for five days by intravenous continuous infusion repeated every 3 weeks. All patients (21 males and 14 females) were evaluable for toxicity. Two patients were not evaluable for response having been removed from protocol treatment due to toxicity and received other treatment during the first course of chemotherapy. Among the evaluable patients there was one complete response in a supraclavicular lymph node lasting four months and one partial liver response lasting three months. The remaining thirty-one patients were non-reponders. Of these one had a stable disease lasting 21 months. The overall objective response rate was 6% (2/35) with a 95% confidence interval of 1%–19%. Twenty-six of the 35 patients have died. The estimated median survival of the entire group was 9 months with a 95% confidence interval of six to eleven months. Renal toxicity was dose-limiting and manifested as increasing serum creatinine (54% of patients), proteinuria (51%) and hematuria (9%). One patient experienced grade 4 creatinine increase, proteinuria and acute renal failure. Other toxicities included nausea (71%), vomiting (51%), malaise (23%), weakness (20%), alopecia (17%), diarrhea (17%), anorexia (14%), transaminase (SGOT, SGPT) increase (14%), constipation (14%), alkaline phosphatase or 5nucleotidase increase (9%), and fever (9%). Hematologictoxicity (granulocytopenia, leukopenia, and anemia) was generally mild and infrequent (29%, only one patient had grade 4 granulocytopenia). Overall 9 patients (26%) had at least one grade 3 toxicity. We conclude that merbarone at this dose and schedule has detectable but minimal activity in the treatment of metastatic malignant melanoma and given the significant renal toxicity this schedule does not merit further evaluation in this disease. 相似文献
25.
Kristl Julijana Pečar Slavko Šmid-Korbar Jelka Schara Milan 《Pharmaceutical research》1991,8(4):505-507
The effects of a polymer, the Li-salt copolymer of methyl-methacrylic acid, and its methyl ester on the motion of drug molecules in hydrocolloids were studied. The investigation was carried out by means of electron paramagnetic resonance (EPR) using the model nitroxide tempol, and the spin-labeled drugs lidocaine (si-lid) and dexamethasone (sl-dex). Synthesis of sl-dex was performed. Spin-labeled molecules dissolved in hydrocolloids undergo a fast reorientation motion. The decreasing order of rotational correlation times () —sl-dex > si-lid > tempol—suggests that the size and the shape of the molecules strongly affect their motion. The inhibition of motion of larger molecules depends also on their flexibility. The values indicate proportionality of the microviscosity of hydrocolloids to the polymer concentration. Rotational motion is dependent on the local environment conditioned by the free spaces between polymer molecules. 相似文献
26.
Babic SH Kokol P Podgorelec V Zorman M Sprogar M Stiglic MM 《Journal of medical systems》2000,24(1):43-52
Decision support systems that help physicians are becoming a very important part of medical decision making. They are based on different models and the best of them are providing an explanation together with an accurate, reliable, and quick response. One of the most viable among models are decision trees, already successfully used for many medical decision-making purposes. Although effective and reliable, the traditional decision tree construction approach still contains several deficiencies. Therefore we decided to develop and compare several decision support models using four different approaches. We took statistical analysis, a MtDeciT, in our laboratory developed tool for building decision trees with a classical method, the well-known C5.0 tool and a self-adapting evolutionary decision support model that uses evolutionary principles for the induction of decision trees. Several solutions were evolved for the classification of metabolic and respiratory acidosis (MRA). A comparison between developed models and obtained results has shown that our approach can be considered as a good choice for different kinds of real-world medical decision making.Art (from Latin ars meaning skill) is the skill in doing or performing that is attained by study, practice, or observation 相似文献
27.
Milan R. Henzl 《American Journal of Drug Delivery》2005,3(4):227-237
Vaginally applied imidazoles are the first-line treatment of vulvovaginal candidiasis (VVC). The need to develop a less messy and more patient acceptable treatment regimen led to the development of a treatment schedule from the original 3 weeks to 7 days and, then, to 3 days. Finally, it was attempted to design a single-dose treatment regimen. Currently in the US, three single-dose vaginal preparations are available: 2% butoconazole sustained release (SR) [100mg butoconazole; Gynazole-1®], 6.5% tioconazole (300mg tioconazole; Vagistat-1®), and 2% miconazole vaginal ovule (Monistat1®, combination pack providing an ovule of 1200mg of miconazole and 2% monistat cream for external use). Clotrimazole 500mg single-dose vaginal tablet was used earlier and has been withdrawn from the market. In clinical studies, treatment success is measured by the regression of signs and symptoms of VVC (clinical cure) and by the negative mycological cultures (microbiological cure). 2% butoconazole SR has been formulated in an emulsion that adheres to wet surfaces of vaginal mucosa infected with Candida albicans. After the single dose, butoconazole is gradually released from the emulsion in a sustained release fashion for 3–6 days and acts on the fungus. The results of treatment with 2% butoconazole SR were equivalent to a 7-day schedule with 2% miconazole. Adverse effects have been infrequent and usually mild. 2% butoconazole in the SR bioadhesive formulation is drug-sparing compared with treatment regimens providing a total of 300–700mg of imidazoles in 3–7 days. The second single-dose preparation, 6.5% tioconazole, for VVC provides tioconazole 300mg in a vaginal ointment. This compound has been compared with 2% miconazole in a separate and independent set of clinical trials; 2% miconazole was superior to 6.5% tioconazole in the microbiological cure rates at the first follow-up examination. The success of a single-dose antifungal treatment also depends upon the vehicle used to deliver the active drug to the target tissue. In case of 2% butoconazole SR the vehicle is formulated as a hydrophilic emulsion that adheres to the surface of the moist vaginal mucosa for 3–6 days. Representative of the orally active preparations is a single dose of fluconazole 150mg. The efficacy results of oral fluconazole are similar to the 7-day vaginal antifungal preparations; however, there is the possibility of the development of resistance and systemic adverse effects affecting the liver and kidneys. The sustained-release technology used for single dose of 2% butoconazole is an innovative approach to vaginal drug delivery. 相似文献
28.
29.
Morphine (30 mg/kg i.p.) produced a hypothermic effect in restrained rats which was antagonized by naloxone pretreatment (10 mg/kg s.c.). This hypothermia was inhibited by deprenyl pretreatment (5 mg/kg i.p.) and by beta-phenylethylamine treatment (25 mg/kg i.p.). However, the effect of morphine was partially potentiated when a higher dose of deprenyl (10 mg/kg i.p.) was administered. Pretreatment with clorgyline (1 mg/kg i.p.) potentiated the morphine-induced hypothermia. In contrast, the effect of morphine was antagonized when a higher dose of clorgyline was used (5 mg/kg i.p.). Based on these results, a possible role of brain serotonin and dopamine in the thermoregulatory effects of morphine is proposed in this paper. 相似文献
30.
Mandruzzato G Antsaklis A Botet F Chervenak FA Figueras F Grunebaum A Puerto B Skupski D Stanojevic M;WAPM 《Journal of perinatal medicine》2008,36(4):277-281
Perinatal mortality and morbidity is markedly increased in intrauterine growth restricted (IUGR) fetuses. Prenatal identification of IUGR is the first step in clinical management. For that purpose a uniform definition and criteria are required. The etiology of IUGR is multifactorial and whenever possible it should be assessed. When the cause is of placental origin, it is possible to identify the affected fetuses. The major complication is chronic fetal hypoxemia. By monitoring the changes of fetal vital functions it is thus possible to improve both management and outcome. The timing of delivery is crucial but the optimal management scheme has not yet been identified. When IUGR is identified at very early gestational ages, serial assessments of the risk of continuing the in utero fetal life under adverse conditions versus the risks of the prematurity should be performed. Delivery of IUGR fetuses should take place in centers where appropriate neonatal assistance can be provided. Careful monitoring of the IUGR fetus during labor is crucial as the IUGR fetus can quickly decompensate once uterine contractions have started. 相似文献